Publications by authors named "Bao Toan Nguyen"
Prospective validation study: a non-invasive circulating tumor DNA-based assay for simultaneous early detection of multiple cancers in asymptomatic adults.
BMC Med
February 2025
Background: Non-invasive multi-cancer early detection (MCED) tests have shown promise in enhancing early cancer detection. However, their clinical utility across diverse populations remains underexplored, limiting their routine implementation. This study aims to validate the clinical utility of a multimodal non-invasive circulating tumor DNA (ctDNA)-based MCED test, SPOT-MAS (Screening for the Presence Of Tumor by DNA Methylation And Size).
View Article and Find Full Text PDFA consultation and work-up diagnosis protocol for a multicancer early detection test: a case series study.
Future Sci OA
December 2024
The emergence of multicancer early detection (MCED) tests holds promise for improving early cancer detection and public health outcomes. However, positive MCED test results require confirmation through recommended cancer diagnostic imaging modalities. To address these challenges, we have developed a consultation and work-up protocol for definitive diagnostic results post MCED testing, named SPOT-MAS.
View Article and Find Full Text PDFMultimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization.
Elife
October 2023
Article Synopsis
- The study introduces a new assay called SPOT-MAS that combines multiple analysis techniques to detect different types of cancer using circulating tumor DNA (ctDNA).
- SPOT-MAS was tested on a large group of 738 patients with various cancers and 1550 healthy controls, successfully identifying cancers with a sensitivity of 72.4% and high specificity.
- The assay performs well for early-stage cancers and shows promise for being more cost-effective compared to other ctDNA tests due to its lower sequencing depth requirements.
Fragment length profiles of cancer mutations enhance detection of circulating tumor DNA in patients with early-stage hepatocellular carcinoma.
BMC Cancer
March 2023
Article Synopsis
- - Late detection of hepatocellular carcinoma (HCC) leads to a low survival rate, but liquid biopsy assays that detect circulating tumor DNA (ctDNA) offer a potential early non-invasive detection method; however, challenges exist due to normal cell mutations and tumor diversity.
- - Researchers developed a classification model using deep sequencing of 13 HCC-associated genes, analyzing ctDNA fragment length profiles to distinguish between HCC patients and healthy individuals.
- - The model demonstrated strong performance in identifying HCC, with an AUC of 0.88 and 89% sensitivity in the discovery cohort, and similar results in an independent validation cohort, indicating potential for further clinical studies.
Circulating DNA methylation profile improves the accuracy of serum biomarkers for the detection of nonmetastatic hepatocellular carcinoma.
Future Oncol
December 2022
Article Synopsis
- * Researchers identified unique methylation markers from cell-free DNA of HCC patients and used them to train machine learning models, which successfully differentiated HCC patients from high-risk individuals without the cancer in testing.
- * By integrating these methylation markers with existing serum biomarkers in a commercial test, they achieved improved detection accuracy for HCC, demonstrating potential for early diagnosis.
Clinical validation of a ctDNA-Based Assay for Multi-Cancer Detection: An Interim Report from a Vietnamese Longitudinal Prospective Cohort Study of 2795 Participants.
Cancer Invest
February 2023
Article Synopsis
- The SPOT-MAS assay detects five common cancers in Vietnam by analyzing circulating tumor DNA in blood samples.
- It was validated in the K-DETEK clinical trial involving 2,795 participants across 14 sites, showing a 60% positive predictive value and 83.3% accuracy in identifying tumor locations.
- The study suggests that SPOT-MAS can be used as a complementary method for early cancer detection, potentially leading to timely treatment opportunities.
Pathogenic Variant Profile of Hereditary Cancer Syndromes in a Vietnamese Cohort.
Front Oncol
January 2022
Background: Hereditary cancer syndromes (HCS) are responsible for 5-10% of cancer cases. Genetic testing to identify pathogenic variants associated with cancer predisposition has not been routinely available in Vietnam. Consequently, the prevalence and genetic landscape of HCS remain unknown.
View Article and Find Full Text PDFPineapple is an economically significant plant and the third most important fruit crop in the tropical and subtropical regions of the world. In this study, fermentation of pineapple juice with probiotic bacteria and strains as well as changes of some properties in the beverage during storage were investigated. All tested strains exhibited good growth properties on pineapple juice without supplementation of any nutrient compounds.
View Article and Find Full Text PDFArticle Synopsis
- Scientists found that using tiny particles called nanoparticles with special polymers can help reduce clumping in certain materials.
- They tested how these combinations behave by looking at light in different ways, both in liquid and when spread out as thin layers.
- The tiny particles attract parts of the polymer, which helps keep them from sticking together, showing a new method to control how these materials combine.
Selection for aluminium tolerance in embryogenic lines of Citrus sinensis L. and C. aurantium L.
Meded Rijksuniv Gent Fak Landbouwkd Toegep Biol Wet
February 2004
The Citrus cultivars 'Amargo' and 'Pineapple' produce embryogenic cultures on two types of sugars, galactose and lactose. Two percent lactose is optimal for both cultivars; embryogenic callus is produced 8-10 weeks after inoculation. Whereas 2% galactose is optimal for 'Amargo', it is 3% for 'Pineapple'.
View Article and Find Full Text PDF